|
May 14
|
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
|
|
May 9
|
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
|
|
Apr 15
|
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
|
|
Apr 1
|
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
|
|
Mar 7
|
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Dec 12
|
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
|
|
Dec 4
|
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
|
|
Sep 5
|
Viracta Therapeutics to Host R&D Day on October 4, 2023
|